Proteomics Gives Us the Cancer Traffic Report - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Proteomics Gives Us the Cancer Traffic Report

In cancer genotyping, genomics provides the blueprint, while proteomics tells us what has been built – so let's integrate them

  • By

  • Kayla Sparks

  • Emanuel "Chip" Petricoin

  • September 3, 2026

  • 12 min

Share

Clinical Report: Proteomics Gives Us the Cancer Traffic Report

Background

The integration of genomics and proteomics is crucial in oncology as it bridges the gap between a tumor's genetic potential and its functional activity. While genomic testing has advanced cancer diagnostics, it does not fully capture the dynamic processes that influence tumor behavior and treatment response.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

  • Genomics reveals potential tumor capabilities, while proteomics shows actual tumor activity.
  • Functional proteomics can identify active signaling pathways that may not correlate with genomic mutations.
  • Patients with similar genomic alterations can exhibit different responses to targeted therapies.
  • Acquired resistance in tumors can occur despite stable genomic profiles.
  • Proteomics can uncover therapeutic vulnerabilities that are not evident through genomic analysis.

Clinical Implications

Incorporating functional proteomics into clinical practice may enhance the accuracy of therapy selection. Clinicians should consider both genomic and proteomic data.

Conclusion

The integration of functional proteomics into oncology diagnostics represents a significant advancement in precision medicine.

Related Resources & Content

  1. the analytical scientist, Embracing the Proteogenomic Toolkit, 2017 -- Embracing the Proteogenomic Toolkit
  2. the pathologist, Embracing the Proteogenomic Toolkit, 2017 -- Embracing the Proteogenomic Toolkit
  3. the pathologist, Driving Discovery, 2015 -- Driving Discovery
  4. the analytical scientist, Proteomics Meets Precision Oncology with PROTsi, 2025 -- Proteomics Meets Precision Oncology with PROTsi
  5. ASCO Living Guideline, Version 2026.3.2 | Journal of Clinical Oncology, 2026 -- Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations
  6. International Cancer Proteogenome Consortium | Office of Cancer Clinical Proteomics Research -- International Cancer Proteogenome Consortium
  7. Plasma proteomics predicts pathological complete response and reveals LIF as a potential mediator of resistance to neoadjuvant immunochemotherapy in resectable NSCLC - PMC -- Plasma proteomics predicts pathological complete response
  8. Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2 | Journal of Clinical Oncology
  9. International Cancer Proteogenome Consortium | Office of Cancer Clinical Proteomics Research
  10. Plasma proteomics predicts pathological complete response and reveals LIF as a potential mediator of resistance to neoadjuvant immunochemotherapy in resectable NSCLC - PMC

Original Source(s)

Proteomics Gives Us the Cancer Traffic Report

  • by Kayla Sparks, Emanuel "Chip" Petricoin

  • September 3, 2026

Related Content

Estriol may ease menopause-related cognitive decline

Women reported improvement across 6 cognitive domains during 12 months of estriol-based treatment, while murine models suggested a potential astrocyte-mediated mechanism.

India’s TB Labs Face a Capacity Gap

Researchers identified gaps in molecular diagnostics, drug susceptibility testing, and treatment monitoring

  • September 3, 2026

  • 3 min
Exercise may protect memory after sleep loss

A 20-minute exercise bout and 90-minute nap produced similar episodic memory performance following 30 hours of wakefulness but engaged distinct neural mechanisms.